Octave Bioscience nabs $32m Series B
Octave Bioscience, a developer of a care management platform for multiple sclerosis and other neurodegenerative diseases, has closed $32 million in Series B financing.
Octave Bioscience, a developer of a care management platform for multiple sclerosis and other neurodegenerative diseases, has closed $32 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination